Author: admin

DelveInsight’s report, “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2036” provides a comprehensive analysis of the Inflammatory Bowel Disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Inflammatory Bowel Disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Bowel Disease Market Forecast

Some of the key facts of the Inflammatory Bowel Disease Market Report:

• The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In May 2026, Mabwell announced that its novel therapeutic asset, 9MW5211, has successfully received Investigational New Drug (IND) clearance from the US FDA, allowing the candidate to advance into human clinical trials. Touted as a world-first in its specific therapeutic class, 9MW5211 utilizes innovative molecular engineering to target specialized disease pathways, and this regulatory clearance validates Mabwell’s manufacturing quality and preclinical safety profiles while marking a major milestone for the company’s global clinical expansion.

• In May 2026, new long-term data from Eli Lilly and Company showed that patients with moderately to severely active ulcerative colitis treated with mirikizumab achieved durable disease clearance through four years of continuous treatment.

• In May 2026, Johnson & Johnson announced results from the Phase III (FUZION) study evaluating guselkumab in adults with active perianal fistulizing Crohn’s disease. The study met its primary endpoint of combined fistula remission at Week 24.

• In April 2026, AbbVie announced that it has submitted an application to the US FDA seeking approval for risankizumab for SC induction for the treatment of adult patients with moderately to severely active Crohn’s disease.

• In March 2026, AbbVie announced positive topline results from phase III (AFFIRM) study evaluating risankizumab (SKYRIZI) subcutaneous induction in patients with crohn’s disease.

• In February 2026, Sanofi and Teva announced that duvakitug (TEV-574/SAR447189) demonstrated clinically meaningful and durable efficacy in Phase IIb maintenance studies across both ulcerative colitis and Crohn’s disease, supporting its continued evaluation as a potential next-generation therapy in inflammatory bowel disease.

• In February 2026, ABVX / Nasdaq: ABVX), a clinical-stage biotech company developing therapies that leverage the body’s natural regulatory pathways to maintain immune balance in chronic inflammatory conditions, has announced new preclinical and clinical findings for obefazimod. The data were presented at the European Crohn’s and Colitis Organisation Annual Congress. These results strengthen the evidence supporting obefazimod’s development in Inflammatory bowel disease, showcasing its anti-fibrotic effects in Crohn’s disease, along with a favorable safety and tolerability profile, rapid symptom relief, and further validation of its mechanism of action through upregulation of the miR-124 to restore immune homeostasis.

• In January 2026, Abivax announced that (ABTECT-UC) Phase III maintenance topline results for ABX464 are expected in late Q2 2026, followed by a planned US regulatory filing in late 2026, subject to outcomes. The company also confirmed that the (ENHANCE-CD) Phase IIb Crohn’s disease induction study is ongoing, with topline results expected in late 2026, supporting expansion into broader IBD indications.

• In May 2025, ALPCO introduced its Calprotectin Immunoturbidimetric Assay in Europe to aid in diagnosing inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis. The assay, already FDA-cleared and IVDD-certified, is designed to help differentiate IBD from irritable bowel syndrome (IBS) when combined with other clinical information.

• In January 2025, Eli Lilly and Company reported that the U.S. Food and Drug Administration (FDA) has granted approval to Omvoh® (mirikizumab-mrkz) for adults with moderately to severely active Crohn’s disease. With this approval, Omvoh is now authorized in the U.S. for two inflammatory bowel diseases (IBD), following its October 2023 approval as the first-in-class therapy for moderately to severely active ulcerative colitis (UC) in adults.

• In 2025, the total diagnosed prevalent cases of IBD in the United States were found to be ~3 million which was highest among the 7MM.

• Among the total diagnosed prevalent cases of IBD majority of cases were accounted by ulcerative colitis accounting ~57% of total cases of IBD cases in the United States in 2025.

• In 2025, there were more than one million cases falling in the age group of 18-44 years which was highest among other age group for IBD in the United States followed by 45-64 years.

• Ulcerative colitis cases based on severity of disease were more in moderate to severe (~60%) than in mild in EU4 and the UK in 2025.

• Crohn’s disease is typically more severe than ulcerative colitis but is slightly less common. The disease can occur at any age, but Crohn’s disease is most often diagnosed in adolescents and adults between 20 and 30.

• Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others

• Key Inflammatory Bowel Disease Therapies: Mirikizumab (OMVOH), Risankizumab (SKYRIZI), ABX464 (obefazimod), Tulisokibart (MK-7240), RHB-204, Guselkumab (TREMFYA), RINVOQ (upadacitinib), STELARA (ustekinumab), Obefazimod, MORF-057, Blautix, BEKINDA (RHB-102), TRP-8802, Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others

• The Inflammatory Bowel Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

Inflammatory Bowel Disease Overview

Irritable Bowel Syndrome is a common disorder that affects the large intestine (colon). It is characterized by a group of symptoms that occur together, including abdominal pain or discomfort, bloating, and changes in bowel habits such as diarrhea, constipation, or both. IBS is a chronic condition that can vary in severity and typically requires long-term management.

Get a Free sample for the Inflammatory Bowel Disease Market Report:

https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market

Inflammatory Bowel Disease Epidemiology

The Inflammatory Bowel Disease epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Inflammatory Bowel Disease (IBD) Diagnosed Prevalent Cases

• Inflammatory Bowel Disease (IBD) Type-specific Diagnosed Cases

• Inflammatory Bowel Disease (IBD) Severity-specific Diagnosed Cases

• Inflammatory Bowel Disease (IBD) Age-specific Diagnosed Cases

• Inflammatory Bowel Disease (IBD) Treated Cases

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Epidemiology Forecast

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Bowel Disease Therapies and Key Companies

• Mirikizumab (OMVOH): Eli Lilly and Company

• Risankizumab (SKYRIZI): AbbVie

• ABX464 (obefazimod): Abivax

• Tulisokibart (MK-7240): Merck

• RHB-204: Redhill Biopharma

• Guselkumab (TREMFYA): Johnson & Johnson

• RINVOQ (upadacitinib): AbbVie

• STELARA (ustekinumab): Janssen Pharmaceuticals

• Obefazimod: Abivax

• MORF-057: Morphic Therapeutic

• Blautix: CJ Bioscience/4D Pharma

• BEKINDA (RHB-102): RedHill Biopharma

• TRP-8802: Tryp Therapeutics

• Mirikizumab: Eli Lilly and Company

• Filgotinib: Gilead/ Galapagos

• AMT-101: Applied Molecular Transport

• PN-943: Protagonist Therapeutics

• Tremfya: Janssen

• Brazikumab: AstraZeneca

Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease Market Drivers

• Rising global prevalence of IBD: Increasing incidence of Crohn’s disease and ulcerative colitis, particularly in developed and emerging markets, is expanding the treated patient pool.

• Strong adoption of biologics and advanced therapies: TNF inhibitors, IL-12/23 and IL-23 inhibitors, integrin blockers, and JAK inhibitors are driving market growth in moderate-to-severe disease.

• Shift toward early and aggressive treatment strategies: Earlier use of targeted therapies to prevent disease progression and complications is supporting higher treatment uptake.

• Robust clinical pipeline and innovation: Continued development of next-generation biologics, oral small molecules, and novel mechanisms is sustaining long-term market expansion.

• Improved diagnosis and disease awareness: Advances in endoscopy, imaging, biomarkers, and patient awareness are enabling earlier diagnosis and treatment initiation.

Inflammatory Bowel Disease Market Barriers

• High cost of biologic therapies: Premium pricing of branded biologics and advanced therapies creates reimbursement challenges and limits access in cost-sensitive markets.

• Safety and tolerability concerns: Risks such as infections, malignancies, and long-term immunosuppression may restrict widespread or prolonged use.

• Loss of response and treatment resistance: Primary non-response and secondary loss of efficacy remain significant challenges in long-term disease management.

• Intense market competition: Crowded therapeutic classes and biosimilar entry are increasing pricing pressure and complicating differentiation.

• Complex treatment pathways and patient heterogeneity: Variable disease presentation and response make optimal therapy selection challenging, slowing treatment optimization.

Scope of the Inflammatory Bowel Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others

• Key Inflammatory Bowel Disease Therapies: Mirikizumab (OMVOH), Risankizumab (SKYRIZI), ABX464 (obefazimod), Tulisokibart (MK-7240), RHB-204, Guselkumab (TREMFYA) RINVOQ (upadacitinib), STELARA (ustekinumab), Obefazimod, MORF-057, Blautix, BEKINDA (RHB-102), TRP-8802, Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others

• Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies

• Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement

To know more about Inflammatory Bowel Disease companies working in the treatment market, visit @ Inflammatory Bowel Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Inflammatory Bowel Disease Market Report Introduction

2. Executive Summary for Inflammatory Bowel Disease

3. SWOT analysis of Inflammatory Bowel Disease

4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance

5. Inflammatory Bowel Disease Market Overview at a Glance

6. Inflammatory Bowel Disease Disease Background and Overview

7. Inflammatory Bowel Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Bowel Disease

9. Inflammatory Bowel Disease Current Treatment and Medical Practices

10. Inflammatory Bowel Disease Unmet Needs

11. Inflammatory Bowel Disease Emerging Therapies

12. Inflammatory Bowel Disease Market Outlook

13. Country-Wise Inflammatory Bowel Disease Market Analysis (2022–2036)

14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies

15. Inflammatory Bowel Disease Market Drivers

16. Inflammatory Bowel Disease Market Barriers

17. Inflammatory Bowel Disease Appendix

18. Inflammatory Bowel Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Bowel Disease Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly, Gilead

DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hyperphosphatemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperphosphatemia Market Forecast

Some of the key facts of the Hyperphosphatemia Market Report:

• The Hyperphosphatemia market size is anticipated to grow with a significant CAGR during the study period (2022-2036)

• According to DelveInsight, in 2025, in the United States, the prevalent cases of CKD were found to be highest in the age group 65 and above with approximately 1,961,000 cases and followed by age group 45–64 with approximately 1,056,000 cases.

• There are five stages of CKD defined as Stage 1–5. As per the CDC estimates, the prevalence of ESRD doubled between 1990 and 2016. Secondary findings in 2016 suggested a point prevalence of 2,206 per million population for the ESRD treated pool; the prevalence of dialysis treatment was 1,553 per million, whereas the prevalence of functioning kidney transplant was 653 per million. Furthermore, nearly 71% of patients are on dialysis, and 29% live with a kidney transplant.

• In a large community-based cohort study from the QICKD trial, hyperphosphatemia (>1.50 mmol/L) was observed in 4.3% of patients with CKD stages I–II and 22.4% of patients with CKD stages III–V who experienced cardiovascular events, highlighting the increasing burden of hyperphosphatemia with worsening CKD severity.

• Hyperphosphatemia is observed in approximately 1.4% of patients with CKD stages I–II, while its prevalence increases to around 2.3% in patients with CKD stages III–IV

• Elevated serum phosphate levels are associated with increased risks of vascular calcification, cardiovascular disease, all-cause mortality, and hospitalization, particularly among dialysis-dependent CKD populations.

• Hyperphosphatemia is a common laboratory abnormality encountered by nephrologists. In patients with ESRD, the prevalence of hyperphosphatemia varies from 50 to 74%. Among children with oncologic disorders who received liposomal amphotericin, nearly 45% of children developed hyperphosphatemia.

• Key Hyperphosphatemia Companies: Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharmaceuticals, FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others

• Key Hyperphosphatemia Therapies: Tenapanor (XPHOZAH), Sevelamer Carbonate (RENVELA), Lanthanum carbonate (FOSRENOL), Oxylanthanum Carbonate, TS-172, AP-301, VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela®, MCI-196, and others

• The Hyperphosphatemia epidemiology based on gender analyzed that Hyperphosphatemia occurs in both men and women

• The Hyperphosphatemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hyperphosphatemia pipeline products will significantly revolutionize the Hyperphosphatemia market dynamics.

Hyperphosphatemia Overview

A rise in serum phosphate levels exceeding 4.5 mg/100 mL indicates the presence of hyperphosphatemia. In individuals with chronic kidney disease (CKD), the illness is typically brought on by a decline in renal function, which causes phosphate levels to rise unusually high.

Get a Free sample for the Hyperphosphatemia Market Report

https://www.delveinsight.com/report-store/hyperphosphatemia-market

Hyperphosphatemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hyperphosphatemia Epidemiology Segmentation:

The Hyperphosphatemia market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of Chronic Kidney Disease (CKD)

• Total Diagnosed Prevalent Cases of CKD

• Stage-specific Distribution of CKD

• Total Prevalent Cases of End-Stage Renal Disease (ESRD)

• Number of ESRD patients undergoing Dialysis

• Total Prevalent Cases of Hyperphosphatemia

Download the report to understand which factors are driving Hyperphosphatemia epidemiology trends @ Hyperphosphatemia Epidemiology Forecast

Hyperphosphatemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperphosphatemia market or expected to get launched during the study period. The analysis covers Hyperphosphatemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hyperphosphatemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hyperphosphatemia Therapies and Key Companies

• Tenapanor (XPHOZAH): Ardelyx

• Sevelamer Carbonate (RENVELA): Sanofi

• Lanthanum carbonate (FOSRENOL): Takeda Pharma

• Oxylanthanum Carbonate: Unicycive Therapeutics

• TS-172: Taisho Pharma

• AP-301: Alebund Pharmaceuticals

• VELPHORO/P-TAL: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS

• KIKLIN: Astellas pharma

• Oxylanthanum Carbonate (OLC): Unicycive Therapeutics

• Ibsrela (tenapanor): Ardelyx

• PT20: Shield Therapeutics

• KHK7791: Kyowa Kirin Co., Ltd.

• Tenapanor: Ardelyx

• VS-505: Shanghai Alebund Pharma

• Sevelamer Carbonate (GZ419831): Sanofi

• Lanthanum Carbonate (BAY77-1931): Bayer

• Ferric Citrate: Keryx Biopharma

• PA21: Kissei Pharma

• TS-172: Taisho Pharma

• AP-306: Alebund Pharmaceuticals

• calcium acetate: Nabi Biopharmaceuticals

• ASP1585: Astellas Pharma Inc

• SBR759A: Novartis

• Renvela®: Sanofi

• MCI-196: Mitsubishi Tanabe Pharma

Discover more about therapies set to grab major Hyperphosphatemia market share @ Hyperphosphatemia Treatment Market

Hyperphosphatemia Market Drivers

• Rising Prevalence of Chronic Kidney Disease (CKD): Increasing numbers of CKD and end-stage renal disease (ESRD) patients are driving demand for hyperphosphatemia treatments.

• Growing Dialysis Population: A larger global population undergoing hemodialysis and peritoneal dialysis contributes significantly to market growth.

• Advancements in Phosphate Binder Therapies: Development of novel phosphate binders with improved efficacy, safety, and patient compliance is expanding treatment options.

• Increasing Awareness and Early Diagnosis: Enhanced monitoring of serum phosphate levels and greater awareness among healthcare professionals support timely treatment initiation.

Hyperphosphatemia Market Barriers

• High Treatment Costs: The long-term cost associated with phosphate binders and chronic disease management can limit patient access.

• Poor Treatment Adherence: High pill burden, gastrointestinal side effects, and dietary restrictions often reduce patient compliance.

• Availability of Generic Alternatives: Market competition from lower-cost generic phosphate binders may impact revenue growth for branded therapies.

• Limited Awareness in Emerging Markets: Underdiagnosis and inadequate renal healthcare infrastructure can restrict market penetration in developing regions.

Scope of the Hyperphosphatemia Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hyperphosphatemia Companies: Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharmaceuticals, FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others

• Key Hyperphosphatemia Therapies: Tenapanor (XPHOZAH), Sevelamer Carbonate (RENVELA), Lanthanum carbonate (FOSRENOL), Oxylanthanum Carbonate, TS-172, AP-301, VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela®, MCI-196, and others

• Hyperphosphatemia Therapeutic Assessment: Hyperphosphatemia current marketed and Hyperphosphatemia emerging therapies

• Hyperphosphatemia Market Dynamics: Hyperphosphatemia market drivers and Hyperphosphatemia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hyperphosphatemia Unmet Needs, KOL’s views, Analyst’s views, Hyperphosphatemia Market Access and Reimbursement

To know more about Hyperphosphatemia companies working in the treatment market, visit @ Hyperphosphatemia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hyperphosphatemia Market Report Introduction

2. Executive Summary for Hyperphosphatemia

3. SWOT analysis of Hyperphosphatemia

4. Hyperphosphatemia Patient Share (%) Overview at a Glance

5. Hyperphosphatemia Market Overview at a Glance

6. Hyperphosphatemia Disease Background and Overview

7. Hyperphosphatemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hyperphosphatemia

9. Hyperphosphatemia Current Treatment and Medical Practices

10. Hyperphosphatemia Unmet Needs

11. Hyperphosphatemia Emerging Therapies

12. Hyperphosphatemia Market Outlook

13. Country-Wise Hyperphosphatemia Market Analysis (2022–2036)

14. Hyperphosphatemia Market Access and Reimbursement of Therapies

15. Hyperphosphatemia Market Drivers

16. Hyperphosphatemia Market Barriers

17. Hyperphosphatemia Appendix

18. Hyperphosphatemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma

DelveInsight’s “Alpha-1 Antitrypsin Deficiency Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Alpha-1 Antitrypsin Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Antitrypsin Deficiency market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Alpha-1 Antitrypsin Deficiency Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market

Some of the key facts of the Alpha-1 Antitrypsin Deficiency Market Report:

• The Alpha-1 Antitrypsin Deficiency (AATD) market size across the 7MM was valued at approximately USD 940 million in 2024 and is projected to expand significantly through 2036, driven by the increasing adoption of approved treatments and the anticipated launch of emerging therapies that are expected to enhance market penetration and broaden treatment options.

• In May 2025, Beam Therapeutics (Nasdaq: BEAM) announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeted base editing treatment developed for alpha-1 antitrypsin deficiency (AATD) a genetic condition that leads to serious lung and liver complications and represents a significant unmet medical need.

• In March 2025, Beam Therapeutics Inc. (Nasdaq: BEAM) announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for BEAM-302, a potential therapy for alpha-1 antitrypsin deficiency.

• In November 2024, Korro Bio has received approval in Australia to initiate the two-part Phase I/IIa REWRITE trial for its investigational therapy, KRRO-110, targeting alpha-1 antitrypsin deficiency (AATD). The approvals were granted by the Australian Bellberry Human Research Ethics Committee (HREC) and the Therapeutic Goods Administration (TGA).

• The US accounts for the largest market size for AATD among the 7MM. The market size for AATD was USD 780 million in 2024.

• According to DelveInsight’s estimates, among EU4 and the UK, Germany accounted for the largest market of in 2024, while the UK accounted for the least in the respective year.

• In the current market, PROLASTIN/PROLASTIN-C/LYNSPAD drug accounted for the major share, which was around USD 750 million in 2024 in the 7MM.

• As emerging treatments like gene therapies (KB408, BEAM-302, and others) and RNA-editing therapy (WAVE-006) move closer to potential approvals, the market could soon offer more durable, minimally invasive options that significantly improve patient quality of life and set new standards in Alpha-1 Antitrypsin Deficiency care.

• Based on DelveInsight’s assessment in 2024, the 7MM had 225,950 prevalent cases of AATD. These are expected to rise due to the rising prevalence of respiratory illnesses, particularly Chronic Obstructive Pulmonary Disease (COPD) and liver diseases associated with AATD (2026−2036).

• Among the 7MM, the US accounted for the highest number of AATD in 2024.

• Among the EU4 and the UK, the UK accounted for the highest number of AATD cases while, Italy had the lowest cases, in 2024.

• Japan accounted for approximately 2,950 cases of AATD in 2024.

• Key Alpha-1 Antitrypsin Deficiency Companies: Grifols, Kamada Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, Mereo BioPharma, AstraZeneca, Sanofi, Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Krystal Biotech, BioMari, AlveoGene, Korro Bio, and others

• Key Alpha-1 Antitrypsin Deficiency Therapies: PROLASTIN-C LIQUID/LYNSPAD, GLASSIA, Inhaled Alpha 1-Antitrypsin (AAT), Fazirsiran (ARO-AAT/TAK-999), Inhaled AAT, Alvelestat (MPH-966), SAR447537 (INBRX-101), WVE-006, BEAM-302, NTLA-3001, KB408, BMN 349, AVG-001, KRRO-110, and others

• The Alpha-1 Antitrypsin Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alpha-1 Antitrypsin Deficiency pipeline products will significantly revolutionize the Alpha-1 Antitrypsin Deficiency market dynamics.

Alpha-1 Antitrypsin Deficiency Overview

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that affects the liver and lungs. It occurs when there is a deficiency in the production of alpha-1 antitrypsin (AAT) protein, which is mainly produced by the liver and helps protect the lungs from damage caused by inflammation. Without enough AAT, the walls of the lungs can be damaged by enzymes released from white blood cells, leading to conditions such as emphysema and chronic obstructive pulmonary disease (COPD).

To Know in detail about the Alpha-1 Antitrypsin Deficiency market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alpha-1 Antitrypsin Deficiency Market Forecast

Alpha-1 Antitrypsin Deficiency Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alpha-1 Antitrypsin Deficiency Epidemiology Segmentation:

The Alpha-1 Antitrypsin Deficiency market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalent Cases of Alpha-1 Antitrypsin Deficiency

• Total Diagnosed Prevalent Cases of Alpha-1 Antitrypsin Deficiency

• Genotype-specific Prevalent Cases of Alpha-1 Antitrypsin Deficiency

• Comorbidity-associated Cases of Alpha-1 Antitrypsin Deficiency

Download the report to understand which factors are driving Alpha-1 Antitrypsin Deficiency epidemiology trends @ Alpha-1 Antitrypsin Deficiency Epidemiology Forecast

Alpha-1 Antitrypsin Deficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha-1 Antitrypsin Deficiency market or expected to get launched during the study period. The analysis covers Alpha-1 Antitrypsin Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alpha-1 Antitrypsin Deficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alpha-1 Antitrypsin Deficiency Therapies and Key Companies

• PROLASTIN-C LIQUID/LYNSPAD: Grifols

• GLASSIA: Kamada Pharmaceuticals/Takeda

• Inhaled Alpha 1-Antitrypsin (AAT): Kamada Pharmaceuticals

• Fazirsiran (ARO-AAT/TAK-999): Arrowhead Pharmaceuticals and Takeda

• Inhaled AAT: Kamada Pharmaceuticals

• Alvelestat (MPH-966): Mereo BioPharma/AstraZeneca

• SAR447537 (INBRX-101): Sanofi/Inhibrx Biosciences

• WVE-006: Wave Life Sciences

• BEAM-302: Beam Therapeutics

• NTLA-3001: Intellia Therapeutics

• KB408: Krystal Biotech

• BMN 349: BioMari

• AVG-001: AlveoGene

• KRRO-110: Korro Bio

Discover more about therapies set to grab major Alpha-1 Antitrypsin Deficiency market share @ Alpha-1 Antitrypsin Deficiency Treatment Landscape

Alpha-1 Antitrypsin Deficiency Market Drivers

• Increasing Disease Awareness and Diagnosis: Growing awareness among healthcare professionals and improved genetic testing are leading to earlier and more accurate diagnosis of AATD.

• Emergence of Novel Therapies: Advancements in gene therapy, RNA-based therapies, and next-generation augmentation treatments are expanding the therapeutic landscape.

• Rising Adoption of Augmentation Therapy: Greater utilization of approved augmentation therapies for AATD-associated lung disease continues to support market growth.

• Strong Pipeline Activity: Ongoing clinical development programs targeting the underlying genetic cause of AATD are generating significant interest from patients, clinicians, and investors.

Alpha-1 Antitrypsin Deficiency Market Barriers

• Underdiagnosis and Misdiagnosis: AATD often remains undetected or is mistaken for conditions such as COPD or asthma, limiting patient identification and treatment uptake.

• High Cost of Existing Therapies: Long-term augmentation therapy can be expensive, creating reimbursement and accessibility challenges.

• Limited Patient Population: As a rare genetic disorder, the relatively small patient pool may constrain overall market expansion.

• Restricted Availability of Augmentation Products: Dependence on plasma-derived therapies can create supply limitations and manufacturing challenges.

• Lack of Curative Approved Treatments: Current therapies primarily manage symptoms and disease progression rather than addressing the root genetic defect.

Scope of the Alpha-1 Antitrypsin Deficiency Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Alpha-1 Antitrypsin Deficiency Companies: Grifols, Kamada Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, Mereo BioPharma, AstraZeneca, Sanofi, Inhibrx Biosciences, Wave Life Sciences, Beam Therapeutics, Intellia Therapeutics, Krystal Biotech, BioMari, AlveoGene, Korro Bio, and others

• Key Alpha-1 Antitrypsin Deficiency Therapies: PROLASTIN-C LIQUID/LYNSPAD, GLASSIA, Inhaled Alpha 1-Antitrypsin (AAT), Fazirsiran (ARO-AAT/TAK-999), Inhaled AAT, Alvelestat (MPH-966), SAR447537 (INBRX-101), WVE-006, BEAM-302, NTLA-3001, KB408, BMN 349, AVG-001, KRRO-110, and others

• Alpha-1 Antitrypsin Deficiency Therapeutic Assessment: Alpha-1 Antitrypsin Deficiency current marketed and Alpha-1 Antitrypsin Deficiency emerging therapies

• Alpha-1 Antitrypsin Deficiency Market Dynamics: Alpha-1 Antitrypsin Deficiency market drivers and Alpha-1 Antitrypsin Deficiency market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Alpha-1 Antitrypsin Deficiency Unmet Needs, KOL’s views, Analyst’s views, Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement

To know more about Alpha-1 Antitrypsin Deficiency companies working in the treatment market, visit @ Alpha-1 Antitrypsin Deficiency Clinical Trials and Therapeutic Assessment

Table of Contents

1. Alpha-1 Antitrypsin Deficiency Market Report Introduction

2. Executive Summary for Alpha-1 Antitrypsin Deficiency

3. SWOT analysis of Alpha-1 Antitrypsin Deficiency

4. Alpha-1 Antitrypsin Deficiency Patient Share (%) Overview at a Glance

5. Alpha-1 Antitrypsin Deficiency Market Overview at a Glance

6. Alpha-1 Antitrypsin Deficiency Disease Background and Overview

7. Alpha-1 Antitrypsin Deficiency Epidemiology and Patient Population

8. Country-Specific Patient Population of Alpha-1 Antitrypsin Deficiency

9. Alpha-1 Antitrypsin Deficiency Current Treatment and Medical Practices

10. Alpha-1 Antitrypsin Deficiency Unmet Needs

11. Alpha-1 Antitrypsin Deficiency Emerging Therapies

12. Alpha-1 Antitrypsin Deficiency Market Outlook

13. Country-Wise Alpha-1 Antitrypsin Deficiency Market Analysis (2022–2036)

14. Alpha-1 Antitrypsin Deficiency Market Access and Reimbursement of Therapies

15. Alpha-1 Antitrypsin Deficiency Market Drivers

16. Alpha-1 Antitrypsin Deficiency Market Barriers

17. Alpha-1 Antitrypsin Deficiency Appendix

18. Alpha-1 Antitrypsin Deficiency Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha-1 Antitrypsin Deficiency Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Grifols, Kamada Pharma, Takeda, Arrowhead Pharma, Mereo BioPharma, AstraZeneca, Sanofi